Wednesday, January 24, 2018 10:15 PM ET
Insider purchase at Kala Pharmaceuticals (KALA) prolongs buy activity of Last 90 Days
There was significant purchase activity in Kala Pharmaceuticals shares by an insider today, as revealed in a form 4 document filed with the SEC. One insider — OrbiMed Advisors Llc, 10% Owner — bought 257,285 shares in the company having a market value of approximately $3,828,990. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the purchase of 240,484 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 497,769 shares and have averaged 248,885 shares per transaction over this time period.
The number of insider buy/sell trades at Kala Pharmaceuticals is above that of the 280 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 336 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares traded per transaction by Kala Pharmaceuticals insiders is lower than its peers. Within the peer group there were 48,687,603 shares purchased and 42,207,712 shares sold with company insiders purchasing 29,454 shares on average over this time period.
The data obtained in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.